Boehringer Ingelheim Oncology

InPlay From Briefing.com
InPlay from Briefing.com ... Read News

CANO ACIO - YouTube
This channel is for posting videos associated with the Canadian Association of Nurses in Oncology/Association canadienne des infirmières en oncologie (CANO/A ... View Video

Striverdi Respimat (olodaterol) Inhalation Spray
CI-2 Introduction Sabine Luik, MD Regional Medical Director North America and Senior Vice President Medicine and Regulatory Boehringer Ingelheim Pharmaceuticals, Inc. ... Retrieve Content

How To Become A Medical Science Liaison - About.com Careers
Medical science liaison is a highly competitive role in the pharmaceutical industry. What is a medical science liaison, and how does one become a medical science liaison? ... Read Article

HIGHLIGHTS IN MEDICINE IN 2013 - Boehringer Ingelheim
For Boehringer Ingelheim’s second oncology product, nintedanib in NSCLC, the registration process with authorities has started. Additional registration processes continue in individual markets for pradaxa® in the ... Fetch Content

R &D IN ONCOLOGY: Clinical Trial Overview - Dl.groovygecko.net
R &D IN ONCOLOGY: Clinical Trial Overview Fact Sheet The current focus of Boehringer Ingelheim’s cancer research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition, that ... View Doc

Project Manager Oncology, CTSU, Boehringer Ingelheim
Sandra Hoffmann, Project Manager Oncology, CTSU, Boehringer Ingelheim Sandra studied Ecotrophology in Mönchengladbach, Germany and performed her internship and graduate thesis in high ... Return Doc

ADR List 10.17.14 - Boehringer Ingelheim
Oncology Supply 800-633-7555 Puerto Rico Authorized Distributor of Record Name Customer Service Number Cesar Castillo 787-999-1616 Below is a list of Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) Authorized Distributors of Record for Gilotrif® (afatinib) . ... Get Doc

Ventana To Collaborate With Boehringer Ingelheim On The ...
Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests TUCSON, Ariz. and INGELHEIM, Germany, September 19, 2013 – ... Read Here

Nintedanib - Wikipedia, La Enciclopedia Libre
Nintedanib, conocido con los nombres comerciales de Ofev ® y Vargatef ®, ha sido desarrollado por Boehringer Ingelheim y es un fármaco utilizado para el tratamiento de la fibrosis pulmonar idiopática (FPI) y en conjunto con otros medicamentos para algunos tipos de carcinoma pulmonar no ... Read Article

Bewegtbild Und Medizin: Interview Mit Bert Van Eijk ...
Bewegtbild und Medizin: am 24.06.2014 fand die CTVA Veranstaltung bei Boehringer Ingelheim in Ingelheim am Rhein statt. Bert van Eijk, Director Corporate Marketing, Oncology im CTVA Interview. ... View Video

MISSION/BACKGROUND
Company Profiles – 37 Nippon Boehringer Ingelheim Oncology CNS Metabolic Disease DELEGATE(S) Shigeto Nagao Hideyuki Nishiwaki Isato Ohmine ... Access Full Source

Leerstoel - Wikipedia
Eli Lilly & Boehringer Ingelheim Chair in Biological Psychiatry, titularis: Prof. dr. Koen Demyttenaere; Roche Chair in Gastrointestinal Oncology, titularis: Prof. dr. E. Van Cutsem; Roche Chair in Hematology, titularis: Prof. dr. Gregor Verhoef; ... Read Article

First-Line Afatinib Versus Chemotherapy In Patients With Non ...
Compensated consulting for Boehringer Ingelheim, Clovis Oncology, AstraZeneca, Novartis, Merrimack, Taiho, and Genentech; and has received personal fees from Ariad for consulting. Drs. Massey and Zazulina are employees of Boehringer Ingelheim. Dr. ... Access Doc

ANNOUNCING THE 2014 BOEHRINGER INGELHEIM ONCOLOGY NURSE OF ...
Award recognizes dedication and leadership in field of oncology nursing in Canada Vancouver - (September 3, 2014) — The Board of Directors of the Canadian Association of The Boehringer Ingelheim Oncology Nurse of the Year Award recognizes the unique ... Access Document

Data For Boehringer Ingelheim Oncology Compounds At ESMO Asia ...
Data for Boehringer Ingelheim Oncology Compounds at ESMO Asia 2015 Congress Title Authors Abstract Details BI 1482694* Clinical activity and safety of the EGFR ... View Doc

Tabulated ABCD Boehringer Ingelheim
Boehringer Ingelheim Tabulated Trial Report ABCD Synopsis No.: Name of finished product: 2013 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. American Society of Clinical Oncology (ASCO), Chicago, 30 May- 3 Jun 2008 ... Get Document

Trial Statement Discontinuation 1200 - Boehringer Ingelheim
Statement on discontinuation of the study: Boehringer Ingelheim Oncology made a decision to close study 1200.26 to new enrollment in July 2010. The primary reason was a high screen-failure rate combined with recruitment challenges would ultimately prevent full ... Fetch Full Source

The Scope Of Our Clinical Research - boehringer-ingelheim.nl
9 respiratory, neurology, urology, oncology, immunological disease, including arthritis, transplantation and virology, especially HIV. Where an ... Fetch Document

2009 05 18 BI In Oncology FINAL - Dl.groovygecko.net
Backgrounder BOEHRINGER INGELHEIM AND THE SEARCH FOR NEW TARGETED CANCER TREATMENTS 1. About Boehringer Ingelheim 2. Boehringer Ingelheim’s commitment to cancer ... Retrieve Doc

FOR IMMEDIATE RELEASE Boehringer Ingelheim GmbH - AVEO Oncology
FOR IMMEDIATE RELEASE AVEO Pharmaceuticals Investor Contact: Monique Allaire, AVEO Pharmaceuticals, Inc. (617) 299-5810 Media Contact: Caton Lovett, ... Get Content Here

GROUP MANAGEMENT REPORT 2014 - Boehringer Ingelheim
GROUP MANAGEMENT REPORT 2014 52 GROUP MANAGEMENT REPORT INfORMATION ABOUT ThE GROUP Of cOMPANIEs Net sales by business In the indication area oncology Boehringer Ingelheim has successfully advanced research and development of its pipeline compounds and marketed treatments, with the ... Document Viewer

Which Popular Drugs Are Going Off-Patent In 2013-2016?
Which Popular Drugs Are Going Off-Patent in 2013-2016? Good for consumers; bad for industry's bottom line. Boehringer Ingelheim reported sales of $965 million in 2010. Zyvox (linezolid) is an antiviral manufactured by Pfizer. ... Read Article

The Over-The-Counter Drug Industry - Pharma
The Over-The-Counter Drug Industry. Sales increase as consumers reduce number of doctor visits for minor ailments. Sanofi, Bayer, Pfizer, Boehringer Ingelheim, Merck & Co., Perrigo and Reckitt Benckiser. Market Projections. ... Read Article

Please Enter Title Of Presentation ... - Boehringer Ingelheim
Please enter title of presentation, maximum 4 lines, Senior Vice President Biopharmaceuticals Boehringer Ingelheim Deutschland GmbH. Ingelheim Administration Prescription Medicines Consumer Health Care Animal Boehringer Ingelheim in Biberach is expected - Oncology - Infectious diseases ... Access Doc

NCCN Receives $2 Million In Research Funding From Boehringer ...
Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. “We look forward to working with the NCCN Member Institutions in this joint commitment to researching potential new therapies for patients with these ... View Document

Boehringer Ingelheim Investigational Lung Cancer Treatment ...
Boehringer Ingelheim's investigational lung cancer treatment afatinib* prolongs progression free survival (PFS) for advanced non-small cell lung cancer patie ... View Video

EXHIBITION GUIDE - Evidence-Based Cancer Guidelines, Oncology ...
Bronze Level Sponsors AstraZeneca Boehringer Ingelheim Pharmaceuticals, Inc. HELSINN Lilly Oncology Onyx Pharmaceuticals, Inc., an Amgen subsidiary ... Access Doc

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR ...
REGULATED INFORMATION ... Read News